Home » Authors » Brady Huggett

Articles by Brady Huggett

RenaMed Forms Deal With Genzyme For Up To $43M

Sep. 29, 2005

By Brady Huggett

Kereos Raises $19.5M To Both Detect, Treat Disease

Sep. 20, 2005

By Brady Huggett

Kereos Raises $19.5M To Both Detect, Treat Disease

Sep. 20, 2005

By Brady Huggett

Caliper Adding Size Through $22M NovaScreen Purchase

Sep. 9, 2005

By Brady Huggett

Caliper Adding Size Through $22M NovaScreen Purchase

Sep. 9, 2005

By Brady Huggett

Angry Merck Jurors Point To Public's Distaste For Pharma

Sep. 2, 2005

By Brady Huggett

With Discovery Firms Worth Nothing,' Is Biotech Troubled?

Aug. 12, 2005

By Brady Huggett

With Discovery Firms Worth Nothing,' Is Biotech Troubled?

Aug. 12, 2005

By Brady Huggett

Dyax's Phase I, II DX-88 Data Raise Hopes For Pivotal Trial

July 1, 2005

By Brady Huggett

Dyax's Phase I, II DX-88 Data Raise Hopes For Pivotal Trial

July 1, 2005

By Brady Huggett

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Nov. 27, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for November 27, 2024.
In muscular dystrophies, gene therapies race the clock
BioWorld
Since the isolation of the gene that causes Duchenne muscular dystrophy (DMD), scientists have progressed in understanding the mechanisms that lead to muscular...
Bridgebio, with FDA approval, faces Pfizer in ATTR
BioWorld
With the U.S. FDA approval of Attruby (acoramidis) for transthyretin amyloidosis with cardiomyopathy (ATTR-CM), Bridgebio Pharma Inc. is taking on an industry...
‘Evo’ AI can design complete genomes
BioWorld Science
The development of new machine learning tools like Alphafold and Rfdiffusion has allowed scientists to predict the structure of proteins and design them for drug...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.